Fujioka Shoko, Miyazaki Yusuke, Furuya Hinako, Miyazaki Chika, Katori Nobuyuki, Taniguchi Yoshie
Department of Anesthesiology, The Jikei University School of Medicine, Tokyo, Japan.
JA Clin Rep. 2025 May 4;11(1):25. doi: 10.1186/s40981-025-00788-7.
Wilms tumor is the most common pediatric renal tumor. Tumor extension into the inferior vena cava (IVC) can increase hemorrhage risk during surgical resection, necessitating rapid transfusion. Pediatric patients have lower circulating blood volume, heightening their susceptibility to hemodynamic instability.
A 2-year-old boy with an IVC-extending Wilms tumor underwent nephrectomy. Anticipating hemorrhage, we employed an SL One rapid infusion device via a Broviac™ central venous catheter. During a sudden, high-volume bleeding, transfusion was initiated at 23 mL/min and intermittently increased to 150 mL/min while preload was evaluated using transesophageal echocardiography, rapidly stabilizing hemodynamics. No rapid-transfusion-related complications, such as hyperkalemia or hypothermia, were observed, and the postoperative course was uneventful.
In this pediatric case at high risk for acute blood loss, the SL One provided effective circulatory stabilization without adverse events. Further studies are needed to validate the safety of the SL One in pediatric patients.
肾母细胞瘤是最常见的小儿肾脏肿瘤。肿瘤延伸至下腔静脉(IVC)会增加手术切除期间的出血风险,需要快速输血。小儿患者的循环血容量较低,这增加了他们对血流动力学不稳定的易感性。
一名患有延伸至IVC的肾母细胞瘤的2岁男孩接受了肾切除术。鉴于有出血风险,我们通过一根Broviac™中心静脉导管使用了SL One快速输液装置。在突然发生大量出血期间,以23毫升/分钟的速度开始输血,并间歇性增加至150毫升/分钟,同时使用经食管超声心动图评估前负荷,迅速稳定了血流动力学。未观察到与快速输血相关的并发症,如高钾血症或体温过低,术后病程平稳。
在这个急性失血风险高的小儿病例中,SL One有效地稳定了循环,且无不良事件发生。需要进一步研究来验证SL One在小儿患者中的安全性。